A Study of TQ-B3525 on Tolerance and Pharmacokinetics
A Phase I Study of TQ-B3525 on Tolerance and Pharmacokinetics
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Huaqing Wang, doctor
- Phone Number: +86-022-022-2757483
- Email: huaqingw@163.com
Study Locations
-
-
Tianjin
-
Tianjin, Tianjin, China, 300121
- Recruiting
- People's Hospital of Tianjin
-
Contact:
- Huaqing Wang, doctor
- Phone Number: +86-022-022-2757483
- Email: huaqingw@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Relapsed or refractory lymphoma or advanced solid tumor that diagnosed Pathologically or cytologically diagnosed
- ECOG PS≤1
- Adequate blood cell counts, kidney function and liver function
- Patients should participate in the study voluntarily and sign informed consent
Exclusion Criteria:
- Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history
- Hypertension (systolic BP ≥150 mmHg, diastolic BP ≥90 mmHg) still uncontrollable by one medication
- Hepatitis B virus patients with active replication (DNA> 500 cps / mL), hepatitis C
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: TQ-B3525
|
TQ-B3525 p.o. qd
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dose-Limiting Toxicities (DLT)
Time Frame: Baseline up to 28 days
|
DLT: An adverse event occurring after initiation of TQ-B3525 that met any following criteria:
|
Baseline up to 28 days
|
|
Maximum Tolerated Dose (MTD)
Time Frame: Baseline up to 28 days
|
MTD was defined as the highest dose level studied for which the incidence of first cycle DLT was < 33%.
|
Baseline up to 28 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Huaqing Wang, doctor, People's Hospital of Tianjin Tianjin,China,300121
- Study Chair: Wenqi Jiang, doctor, Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China, 510060
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- TQ-B3525-I-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.